Compare PRHI & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRHI | BGLC |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | Malaysia |
| Employees | 9 | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 10.1M |
| IPO Year | N/A | N/A |
| Metric | PRHI | BGLC |
|---|---|---|
| Price | $0.95 | $4.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 69.0K | ★ 202.4K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $44,664,000.00 | $9,465,006.00 |
| Revenue This Year | $25.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.21 |
| 52 Week Low | $0.42 | $2.01 |
| 52 Week High | $2.83 | $15.60 |
| Indicator | PRHI | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 37.21 |
| Support Level | N/A | $4.05 |
| Resistance Level | N/A | $4.34 |
| Average True Range (ATR) | 0.00 | 0.25 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 12.36 |
Presurance Holdings Inc Formerly Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.